Yuichi Kibe
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Yuichi Kibe has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Atsuya Takeda
Department of Radiology, Keio University School of Medicine, Japan
2 shared publications - Takahisa Eriguchi
Radiation Oncology Center, Ofuna Chuo Hospital, Kamakura, Kanagawa, Japan
2 shared publications - Yuichiro Tsurugai
Radiation Oncology Center, Ofuna Chuo Hospital, Kamakura, Japan
2 shared publications Naoki Nakamura
Radiation Oncology Division, St. Marianna University School of Medicine Hospital, Kawasaki, Kanagawa, Japan
1 shared publication- Naoki Nakamura
Radiation Oncology Division, St. Marianna University School of Medicine Hospital, Kawasaki-shi, Japan
1 shared publication Yohei Oku
Radiation Oncology Center, Ofuna Chuo Hospital, Kamakura, Kanagawa, Japan
1 shared publication
Latest Publications
- 10 June 2025
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 43 (17) , 2027-2028
Importance of Defining Recurrence in Hepatocellular Carcinoma: Local or Both Local and Other Intrahepatic Recurrences?
- 10 June 2025
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 43 (17) , 2027-2028
Importance of Defining Recurrence in Hepatocellular Carcinoma: Local or Both Local and Other Intrahepatic Recurrences?
- 6 June 2025
- Published by Springer Nature in International Journal of Clinical Oncology
- p. 1-8
Palliative radiotherapy for bone metastases: conventional external beam radiotherapy
Conventional external beam radiotherapy (cEBRT) is effective for managing symptomatic bone metastases and continues to be in demand despite advances in stereotactic body radiotherapy. This review provides an overview of cEBRT for bone metastases, with a focus on the following: (1) Initial palliative radiotherapy: randomized controlled trials and meta-analyses have shown that single-fraction cEBRT at 8 Gy is as effective as multifractionated cEBRT for reducing pain due to bone metastases. Single-fraction cEBRT at 8 Gy may be a reasonable option for bone metastases with neuropathic pain in consideration of the burden on patients. The efficacy of radiotherapy for preventing skeletal-related events in bone metastases remains unclear. Prophylactic fixation followed by radiotherapy is recommended for long-bone metastases at high risk of fracture. (2) Palliative reirradiation: reirradiation is indicated for patients with insufficient pain relief or pain progression after initial radiotherapy for bone metastases. In palliative reirradiation for spinal metastases, the tolerance dose of the spinal cord needs to be carefully considered due to the risk of radiation myelitis. (3) Treatment strategies for metastatic spinal cord compression (MSCC) or spinal bone metastases with instability: treatment decisions for MSCC, including radiotherapy or decompression surgery followed by radiotherapy, need to be carefully considered by a multidisciplinary team, including radiation oncologists and orthopedic surgeons. Moderate-dose corticosteroids (dexamethasone bolus of 10–16 mg) are recommended in combination with radiotherapy for MSCC. Spinal instability caused by spinal bone metastases is an indication for fixation surgery, and postoperative radiotherapy needs to be considered.
- 6 June 2025
- Published by Springer Nature in International Journal of Clinical Oncology
- p. 1-8
Palliative radiotherapy for bone metastases: conventional external beam radiotherapy
Conventional external beam radiotherapy (cEBRT) is effective for managing symptomatic bone metastases and continues to be in demand despite advances in stereotactic body radiotherapy. This review provides an overview of cEBRT for bone metastases, with a focus on the following: (1) Initial palliative radiotherapy: randomized controlled trials and meta-analyses have shown that single-fraction cEBRT at 8 Gy is as effective as multifractionated cEBRT for reducing pain due to bone metastases. Single-fraction cEBRT at 8 Gy may be a reasonable option for bone metastases with neuropathic pain in consideration of the burden on patients. The efficacy of radiotherapy for preventing skeletal-related events in bone metastases remains unclear. Prophylactic fixation followed by radiotherapy is recommended for long-bone metastases at high risk of fracture. (2) Palliative reirradiation: reirradiation is indicated for patients with insufficient pain relief or pain progression after initial radiotherapy for bone metastases. In palliative reirradiation for spinal metastases, the tolerance dose of the spinal cord needs to be carefully considered due to the risk of radiation myelitis. (3) Treatment strategies for metastatic spinal cord compression (MSCC) or spinal bone metastases with instability: treatment decisions for MSCC, including radiotherapy or decompression surgery followed by radiotherapy, need to be carefully considered by a multidisciplinary team, including radiation oncologists and orthopedic surgeons. Moderate-dose corticosteroids (dexamethasone bolus of 10–16 mg) are recommended in combination with radiotherapy for MSCC. Spinal instability caused by spinal bone metastases is an indication for fixation surgery, and postoperative radiotherapy needs to be considered.
- 17 November 2021
- Published by Medical Journals Sweden AB in Acta Oncologica
- Vol. 61 (1) , 104-110
Feasibility of marker-less stereotactic body radiotherapy for hepatocellular carcinoma
The feasibility of marker-less stereotactic body radiotherapy (SBRT) for hepatocellular carcinoma (HCC) has not yet been established, and, thus, was examined in the present study.We retrospectively...
- 17 November 2021
- Published by Medical Journals Sweden AB in Acta Oncologica
- Vol. 61 (1) , 104-110
Feasibility of marker-less stereotactic body radiotherapy for hepatocellular carcinoma
The feasibility of marker-less stereotactic body radiotherapy (SBRT) for hepatocellular carcinoma (HCC) has not yet been established, and, thus, was examined in the present study.We retrospectively...
- 27 March 2020
- Published by Medical Journals Sweden AB in Acta Oncologica
- Vol. 59 (8) , 888-894
Local control by salvage stereotactic body radiotherapy for recurrent/residual hepatocellular carcinoma after other local therapies
Background: To clarify local control by salvage stereotactic body radiotherapy (SBRT) for recurrent/residual hepatocellular carcinoma (HCC) compared with initial definitive SBRT for local treatment-naïve HCC. Material and methods: We retrospectively investigated HCC patients that received SBRT between July 2005 and December 2017. We classified HCC tumors as the initial definitive SBRT group (Arm-1; initial definitive SBRT, Arm-2; initial definitive planned SBRT following transarterial chemoembolization (TACE)) and salvage SBRT group (Arm-3; salvage SBRT for recurrent/residual tumors after TACE, Arm-4; salvage SBRT for recurrent/residual tumors after radiofrequency ablation (RFA), Arm-5; salvage SBRT for recurrent/residual other than Arm-3 or Arm-4). Local control was evaluated by mRECIST. Results: We reviewed 389 HCC tumors of 323 patients treated by 35–40 Gy/5 fr. The median follow-up time for local recurrence of tumors was 34.8 months (range, 6.5–99.2). The cumulative local recurrence rates at 3 years of Arm-1–5 were 1.4% (95% CI, 0.3–4.4%), 5.0% (95% CI, 1.6–11.5%), 12.4% (95% CI, 5.7–21.9%), 14.8% (95% CI, 3.3–34.3%) and 7.3% (95% CI, 1.9–18.0%), respectively. The cumulative local recurrence rates at 3 years of initial definitive treatment and salvage treatment groups were 2.8% (95% CI, 1.1–5.6%) and 11.1% (95% CI, 6.3–17.3%), respectively (p=.004). On multivariate analysis, salvage treatment and the tumor diameter were significant risk factors of local recurrence (p = .02, p < .001 respectively). Estimated overall survival at 3 years for all patients in initial definitive treatment and salvage treatment groups were 71.5% (95% CI, 63.4–78.1%) and 66.1% (95% CI, 56.4–74.2%), respectively (p = .20). No treatment-related death caused by SBRT was observed. Conclusions: This analysis showed local control of salvage SBRT for recurrent/residual HCC was significantly worse than that of initial definitive SBRT for local treatment-naïve HCC. However, local control of salvage SBRT was relatively good, and salvage SBRT is one of the favorable treatment options for recurrent/residual HCC.
- 27 March 2020
- Published by Medical Journals Sweden AB in Acta Oncologica
- Vol. 59 (8) , 888-894
Local control by salvage stereotactic body radiotherapy for recurrent/residual hepatocellular carcinoma after other local therapies
Background: To clarify local control by salvage stereotactic body radiotherapy (SBRT) for recurrent/residual hepatocellular carcinoma (HCC) compared with initial definitive SBRT for local treatment-naïve HCC. Material and methods: We retrospectively investigated HCC patients that received SBRT between July 2005 and December 2017. We classified HCC tumors as the initial definitive SBRT group (Arm-1; initial definitive SBRT, Arm-2; initial definitive planned SBRT following transarterial chemoembolization (TACE)) and salvage SBRT group (Arm-3; salvage SBRT for recurrent/residual tumors after TACE, Arm-4; salvage SBRT for recurrent/residual tumors after radiofrequency ablation (RFA), Arm-5; salvage SBRT for recurrent/residual other than Arm-3 or Arm-4). Local control was evaluated by mRECIST. Results: We reviewed 389 HCC tumors of 323 patients treated by 35–40 Gy/5 fr. The median follow-up time for local recurrence of tumors was 34.8 months (range, 6.5–99.2). The cumulative local recurrence rates at 3 years of Arm-1–5 were 1.4% (95% CI, 0.3–4.4%), 5.0% (95% CI, 1.6–11.5%), 12.4% (95% CI, 5.7–21.9%), 14.8% (95% CI, 3.3–34.3%) and 7.3% (95% CI, 1.9–18.0%), respectively. The cumulative local recurrence rates at 3 years of initial definitive treatment and salvage treatment groups were 2.8% (95% CI, 1.1–5.6%) and 11.1% (95% CI, 6.3–17.3%), respectively (p=.004). On multivariate analysis, salvage treatment and the tumor diameter were significant risk factors of local recurrence (p = .02, p < .001 respectively). Estimated overall survival at 3 years for all patients in initial definitive treatment and salvage treatment groups were 71.5% (95% CI, 63.4–78.1%) and 66.1% (95% CI, 56.4–74.2%), respectively (p = .20). No treatment-related death caused by SBRT was observed. Conclusions: This analysis showed local control of salvage SBRT for recurrent/residual HCC was significantly worse than that of initial definitive SBRT for local treatment-naïve HCC. However, local control of salvage SBRT was relatively good, and salvage SBRT is one of the favorable treatment options for recurrent/residual HCC.